Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...
The company's strong cash position gives investors confidence in the gene-editing stock.
Gene therapy has experienced an increasing number of successful human clinical trials, leading to numerous FDA-approved therapies based on recombinant viruses for rare disease, cancer, and other ...
(Nanowerk News) In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy ...
MINNEAPOLIS/ST. PAUL (05/02/2025) — Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system ...
The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, ...
At the WIRED Health summit in Boston on September 9, we hosted some of the leading experts in Crispr, whole-genome sequencing, vaccines, and more for a series of eye-opening conversations and keynotes ...
Researchers at NYU Langone Health propose a model that could explain how cancer cells adapt to environmental stress, an ...
Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical therapies.
A long-standing mystery in cancer treatment is how tumor cells so often become resistant to drugs, even ones they have never encountered before.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results